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ABSTRACT 
Background and Aim: Although oestrogen receptor (ER)-negative breast cancers 
(BC) do not respond to hormone therapy, the response of ER-positive BC is reported 
to be variable which may suggest a dose dependent effect. This study aimed to 
assess the pattern of ER-expression in BC at the protein (IHC) and transcriptome 
(microarray-based gene expression) levels. Materials and Methods: ER IHC 
expression was assessed in a large series of BC including 3649 core biopsies and 
1892 cases prepared as TMA stained using specific antibodies. ESR1 mRNA 
expression was assessed in the METABRIC study (1980 cases) using Linear Models 
for Microarray Data (LIMMA) and results were compared with protein levels. 
Results: IHC data confirmed bimodality of ER expression with 92.2% and 89.2% of 
the cases showed completely negative (<1%) or highly positive (≥70%) expression 
on the cores and TMA respectively. Weak positive cases (1-10%) and intermediate-
expression (11%-69%) cases were infrequent (2.7% & 5.1% and 1.6% & 9.2% in 
cores and TMA respectively) and did not show any survival difference to ER negative 
tumours. When full-face sections of the corresponding excision specimens were 
immunostained, 47% of the ER low/intermediate group were deemed to ER 
negative. Transcriptomic data not only showed significant correlation between ESR1 
mRNA and protein expression levels but also confirmed the bimodality of ER at the 
mRNA levels.  Conclusion: Our study provides further evidence that ER expression 
is bimodal and that it is observed at both mRNA and protein levels. The reported 
poor survival of BC patients with low ER-expression in the early clinical trials may be 
related to the inclusion of ER-negative cases.  
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INTRODUCTION 
Global gene expression studies of breast cancer (BC) have demonstrated that 
oestrogen receptor (ER) is the main determinant of BC molecular profiles and that 
ER positive and negative disease BCs are different diseases 1, 2.  Although several 
randomised clinical trials have demonstrated that ER negative BC does not respond 
to endocrine therapy and the effect of endocrine treatments is restricted to ER 
positive disease, the response of ER positive tumours is variable. Only two thirds of 
ER positive BC patients treated with endocrine therapy respond 3. Several studies 
have reported correlation between the level of ER expression and response to 
endocrine therapy and clinical trials indicate that only 50% of tumours with an Allred 
score of 4–6 respond to endocrine treatments compared to 75%–80% in tumours 
with a score of 7 or 8 3-6.
Before immunohistochemistry (IHC), ER expression was measured by radiolabelled 
ligand binding assays (LBA) using fresh-frozen tumour samples which showed a 
continuum of values. For more than two decades, ER expression has been assessed 
using IHC and is used to predict response to endocrine therapy4, 7. In addition to 
being a prognostic marker, some authors reported that the linear distribution of ER 
expression reported with LBA was observed with IHC 4, 5. However, other authors 
have challenged the concept of ER linear expression and they provided evidence 
that ER expression is essentially bimodal 8, 9. 
Identifying genes with bimodal expression patterns from large-scale gene expression 
profiling data has provided new insights into the distribution of expression of key 
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genes. At the transcriptomic level, there are two different classes of genes. The first 
class is consistent of those with a Gaussian or continuous distribution: two small 
groups of tumours have very high expression and very low expression respectively, 
with the rest; which represent the majority, fall somewhere in between. The second 
class is composed of genes with a bimodal distribution of expression. This class has 
the majority of tumours with either high levels of gene expression or no expression, 
and only a relatively few tumours fall in between 10. Previous studies have reported 
significant correlations between ESR1 expression and the clinical ER status 11. 
ESR1 has a high Bimodality Index score and it can be used to classify samples into 
two distinct expression states 12.
This study aimed to assess the pattern of ER expression, both at the protein (IHC) 
and transcriptome (microarray-based gene expression) levels, to comprehensively 
understand the clinical and biological value of tumours expressing low/intermediate 
levels of ER. To achieve this, we reviewed three cohorts of primary BC: 1) 3649 ER 
IHC stained core biopsies performed at Nottingham City Hospital 2) 1892 cases 
prepared as tissue microarray (TMA) and IHC stained for ER and 3) ESR1 mRNA 
level of 1980 BC cases that were included in the METABRIC (Molecular Taxonomy 
of Breast Cancer International Consortium) study 13. 
MATERIALS AND METHODS
Patients Cohorts
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This study was based on 3 patient’s cohorts and was approved by the Nottingham 
Research Ethics Committee 2 under the title 'Development of a molecular genetic 
classification of breast cancer’. ER was assessed using IHC in the first and second 
cohorts and mRNA in the third cohort. Regarding the level of ER expression, weak 
positive cases are defined as those with ER expression between 1% and 10% while 
intermediate expression cases are defined as those scored between 11% and 69%. 
The negative cases are defined according to the ASCO/CAP guidelines14 with a 
score of <1% while the highly positive cases are defined as those expressing ER in 
70% or more of the tumour cells. 
1) The first cohort comprised a consecutive series of symptomatic and screen 
detected BC patients who had ER status assessed on a preoperative core needle 
biopsy (CNB) at Nottingham City Hospital in routine practice between March 2008 
and November 2014 (n=3649 cases). CNB were fixed, processed and stained 
according to standardised protocol as previously published 15. The primary 
antibodies used were 1D5 (Dako; UK), diluted 1/100 and a pre-diluted SP1 clone 
(Roche; UK).
2) The second cohort comprised 1892 patients diagnosed between 1988 and 1998 
whose BC tissues were prepared as tissue microarray (TMA) as part of the 
previously published Nottingham Tenovus Primary Breast Carcinoma Series 16. This 
is a consecutive well-characterised series of early stage primary operable BC 
patients aged 70 years or less. In this cohort, patients’ outcome, including regional 
and distant events, survival and time to the event, was recorded and annually 
updated. This included BC specific survival (BCSS). Moreover, the clinical details of 
the patients including age and menopausal status as well as the tumour details 
including tumour size, grade, stage, lymphovascular invasion (LVI) and lymph node 
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status were available. TMA sections of this series were stained with the ER antibody 
SP1 clone (Dako, UK), using a dilution 1:150 for 30 minutes incubation. Levels of 
immunohistochemical expression were assessed by microscopic eyeballing as the 
percentage of ER positively stained invasive tumour cells.
3) The third cohort comprised 1980 BC cases that were included in the METABRIC 
cohort 13. In this study, the extracted and purified DNA probes were hybridised to 
Affymetrix SNP 6.0 arrays (Affymetrix, Santa Clara, CA) at the quality control criteria 
established by AROS Applied Biotechnology (Aarhus, Denmark). The Illumina Total 
prep RNA amplification kit (Ambion, Warrington, UK) was used for total extraction 
and purification of total RNA. The generated biotinylated cRNA was hybridised with 
Illumina Human HT-12 v3 Expression Beadchips from the same manufacturer 17. 
The resulted gene expression data from the microarray experiments was statistically 
analysed by applying the Linear Models for Microarray Data (LIMMA) inclusive 
software package that is compatible with the Affymetrix data. LIMMA software 
package comprised Student’s t- test, base 2 logarithms of fold changes between the 
normal and tested samples, log2FC, average expression measurements, t-test 
values, p-values, adjusted p-values, and log-odds of differential expression, B values 
as its primary statistical outputs. In this cohort, the survival data and the ER 
immunostaining was available for 262 cases from Nottingham. 
Immunohistochemistry
Surgical excision specimens of 55 cases from the first cohort that showed a low / 
intermediate ER expression on CNB were immunostained to confirm the level of ER 
expression. These 55 cases comprised 39 from the low ER expression group (ER 
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scored between 1% and 10%) and 16 from the intermediate ER expression group 
(ER scored between 11% and 69%). The immunohistochemistry technique was 
applied to full-face sections that are considered as the “gold standard” for ER 
assessment using the standard protocol. In brief, antigen retrieval was carried out 
using citrate at pH 6.0 for 20 min at the microwave. Manual immunohistochemistry 
staining was used by Novolink Max Polymer Detection Kit, Ref: RE7280-K. 
Peroxidase blocking was done by applying peroxidase block for 5 min. Optimised 
primary antibody, EP1 anti ER Rabbit monoclonal antibody (Dako, Ref- M3643) was 
applied and incubated for 30 minute at room temperature followed by Novolink 
polymer for 30 min and enzyme substrate for 5 min. Then, Novolink haematoxylin 
was added for 6 min to each slide. Finally, the slides were dehydrated and mounted 
by coverslip using DPX (BDH, Leica Microsystems, Newcastle UK). Nuclear ER 
staining was then scored using percent and H-score system by two pathologists 
(AAM and EAR). 
Statistical analysis
For IHC expression, in the first and second cohort, the statistical tests were 
performed using IBM SPSS software version 22 (SPSS Inc., Chicago, IL, USA). The 
data was categorised into three groups, the first group included those cases with ER 
expression scored as <1%. The second group included cases between 1-69%. The 
third group contained cases with ER positive ≥70%  which is similar to the cut-off 
point used by Collins et al.8. 
In the second cohort, additionally, survival curves were analysed using the Kaplan–
Meier method with significance determined by the Log Rank (LR) test. The 
association between subcategories and the clinicopathological variables as well as 
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PgR and HER2 as basic prognostic and predictive markers were evaluated using the 
Chi square test. For all statistical tests, p-value was taken into consideration as a 
significant value when it was <0.05.
For transcriptomic data of the third cohort, 1980 BC cases were used to demonstrate 
the ESR1 gene expression distribution pattern. However, patient outcome and 
immunostaining of ER were only available for 262 cases. These cases were 
subdivided into three subgroups according to the changes in the distribution of the 
curve using the SPSS software. The first cut-off point was 6.5 and the second cut-off 
point was 8.6. The high expression group (group 3) included those cases with ESR1 
expression level of >8.6. Gene expression was compared with protein levels and 
patient outcome. Survival curves were analysed by Kaplan–Meier method with 
significance determined by the LR test and a p-value <0.05 considered significant. 
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RESULTS 
Analysis of the 3649 cases assessed on CNBs showed that the majority of cases 
(92.2%) were either strongly positive (≥70%) or negative (<1%) for ER while weak 
ER positive (1-10%) cases (2.7%) and the intermediate-expression (11-69%) group 
(5.1%) were infrequent. Figure 1 shows the bimodal distribution of ER expression 
where those with <1% expression represented 22.4 % of cases and strong ER 
positive cases represented 69.8 % of the total cases.  To further assess the 
existence and frequency of ER low/intermediate expressing tumours, 55 cases were 
immunostained using full-face sections of excision specimens. Out of those 55 
cases, 26 (47.3%) resulted in negative ER expression on excision specimens while 
29 cases remained in the low/intermediate group; reducing the frequency of low/
intermediate group further to approximately 3.9%.. Regarding the low ER expression 
cases assessed on CNBs (39 cases), 16 cases remained positive for ER while 23 
cases changed into negative ER expression. For the intermediate ER expression 
tumours assessed on CNBs (16 cases), 13 cases remained positive while 3 cases 
changed to the negative ER expression subgroup. Figure 2 illustrated negative, low, 
intermediate and highly positive ER expression cases.
The frequency distribution of ER staining, based on the percentage of ER positive 
tumour cells, in the TMA series of 1892 cases is shown in Figure 3. Similar to those 
in CNBs, this series showed bimodality of expression with the completely negative 
and strongly positive cases representing 89.2% of the cases. Weak and intermediate 
expression of ER was infrequent representing 1.6% and 9.2% of cases, respectively. 
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Due to the small number of cases in the weak positive and intermediate expression, 
they were combined and data was analysed accordingly; negative group (<1%), 
intermediate group (1-69%) and highly positive group (≥70%). The associations of 
these subgroups and other clinicopathological variables, progesterone receptor (PR) 
and HER2 status is shown in Table 1.  The association of the ER subgroup with 
HER2 was highly significant where 25% and 22% of the negative and intermediate 
ER groups were HER2 positive compared to 6% of the strong ER positive groups 
that showed HER2 positivity. Progesterone receptor is an ER dependent protein 18. 
In this study, we assessed the frequency of expression of PR in the TMA series 
using the previously published IHC stained PR 16 and this showed a bimodal 
distribution similar to ER (Figure 4). 
Outcome analysis showed significant association between ER expression groups 
and patients’ outcome (Figure 5; p<0.001, LR=23.5). However, further analysis 
showed no significant survival difference between the ER negative group and the 
intermediate ER expression group (p=0.324 and LR=0.97), while there was a 
difference between the intermediate group and the highly positive group (p=0.022 
and LR=5.21). Expectedly, the difference in patient outcome between the negative 
and highly positive group was highly significant (p<0.001 and LR=22.05). 
Consistent with IHC results, analysis of the METABRIC cases (n=1980) showed a 
bimodal distribution of ESR1 mRNA (Figure 6) with 18.2 % of cases in group one 
(representing the ER negative group) and 72 % in group three (representing the ER 
highly positive group) whilst group two (the ER intermediate group) represented only 
9.8% of cases. There was a significant positive correlation between the ESR1 mRNA 
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and protein expression levels (p-value <0.001). The majority (79%) of ER IHC 
negative cases were in the negative ESR1 mRNA group. In addition, 97.1% of the 
strongly ER IHC positive group belonged to the mRNA highly positive group. 
Interestingly 77.8% of the IHC intermediate group (1-69%) correlated to the negative 
and strongly positive mRNA group (Table 2). Outcome analysis showed significant 
differences between the groups (Figure 7; p=0.001 and LR= 13.28). No significant 
difference between the negative group and the intermediate group was identified 
(p=0.74 and LR=0.10). However, the difference between the highly positive group 
and the intermediate group regarding the patient outcome was significant (p=0.01 
and LR= 6.52). 
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DISCUSSION 
The concept of bimodality and linear distribution of ER expression in breast cancer 
remains a subject of debate. The current study provides evidence that the 
distribution of ER expression is bimodal at both protein and gene expression levels 
using IHC and gene expression microarrays technology respectively. At the protein 
level our data are consistent with the results reported by Collins et al. in which 99% 
of 817 cases of were completely negative or positive 8 and with Nadji et al. who 
showed  that ER IHC in BC is an all-or-none phenomenon 9. In support of our 
findings, several other authors have demonstrated the bimodal distribution of ER 
immunostaining including Bogina et al. (362 cases) 19, Badve et al. (776 cases) 20, 
Pinto et al. (360 cases) 21 and Khoshnoud  et al. (683 cases) 22. 
The Schnitt group have commented on the reproducibility of the continuity of 
expression seen using the LBA when a large population-based study was tested 
using IHC 9. They described the relationship between the real quantity of ER protein 
in the malignant cell nuclei and the apparent amount of ER demonstrated by IHC as 
a highly complex process and related this to the effect of the pre-analytic factors on 
the IHC results 23. The pre-analytical factors and the overall sensitivity of IHC were 
considered as the main explanation for the bimodality of the ER distribution. It has 
been demonstrated that IHC can vary depending on a pre-analytical factors as for 
instance tissue fixation24, 25 and antigen retrieval. Umemura et al demonstrated a 
positive correlation regarding a linear relationship between the LBA and a low 
sensitivity IHC assays. This correlation was reduced using a highly sensitive IHC test 
with nonlinear correlation and the biochemical assays resulted in a shift of the low 
ER cases toward the higher end of ER positivity 26.  This reason was used to explain 
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the low frequency of the low ER cases.  Interestingly although the techniques and 
the testing level used to evaluate ER distribution is totally different, in our study when 
the 1980 cases of METABRIC BC data set were evaluated, the similarity between 
the transcriptomic and proteomic levels were significantly high. Both IHC and mRNA 
levels using large data sets demonstrated the bimodal distribution. Therefore, the 
explanation that the bimodal distribution is a result of the pre-analytical factors or the 
highly sensitive IHC test has to be re-considered. The bimodal gene expression for 
ESR1 using 123 patients was presented previously by Wang et al.12.  Their method 
was also applied to the MDA133 breast cancer microarray dataset27.
This study demonstrated strong correlation between ER protein levels (IHC) and 
ESR1 mRNA levels as assessed using gene expression microarrays. Interestingly a 
large proportion of the IHC intermediate group related to the strong ESR expresser 
group. However, this can be explained by either using different cut-offs in each 
cohort or by the differential translation of ER in some cases. The use of 70% as a 
cut-off to define the intermediate group in this study may have resulted in the 
underestimation of the level of ER positivity defined using ESR mRNA. This study 
also did not assess the role of variable ER expression in the breast cancer 
associated stroma on the strength of the association between ER IHC and ESR 
mRNA levels
At the proteomic as well as the transcriptomic level, our results showed no significant 
difference between the ER negative and the intermediate expression groups and 
outcome. Therefore, our findings raise the clinical question whether patients with low 
positive ER expression are actually a positive cases or the misclassification of ER-
negative cancers as borderline weak ER positive. In this study, approximately 50% of 
the low/intermediate IHC ER positive group changed to ER negative when full-face 
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sections of excision specimens were immunostained. Although this may reflect a 
proportion of cases with false positive ER expression on core biopsies 28, further 
research is needed to evaluate this important group of cases. In this study HER2 
overexpression was more frequent in the low and intermediate ER expresser groups 
compared to the strong ER expresser group. The high frequency of HER2 
overexpression in these tumours may support their aggressive behaviour and that 
their response to therapy may be similar to ER-negative group than to the strong ER 
positive tumours. Some of these tumours would be classified in the luminal B or 
HER2-enriched classes however; further study is warrant to investigate this point.
In conclusion, our study provides further evidence to support the concept that ER 
expression in BC is essentially bimodal with the vast majority of cases being either 
ER negative or strongly ER positive. The biological and clinical significance of the 
intermediate expression group particularly the low ER expression subgroup needs 
further investigation.
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Figure legends: 
Figure 1: The distribution of oestrogen receptor (ER) IHC expression as assessed on core 
needle biopsies (3649 cases) demonstrating the bimodal distribution. 
Figure 2:  Illustrated different levels of ER expression, A) negative ER expression. B) Low 
ER expression. C) Intermediate level of ER expression and D) Highly positive ER 
expression. 
Figure 3: The frequency distribution of ER IHC staining scores in the second cohort (1892 
cases) assessed on tissue microarrays (TMA) showing similar bimodal distribution as figure 
1.
Figure 4: The distribution of progesterone receptor (PR) IHC expression as assessed on the 
second cohort demonstrating the bimodal distribution similar to ER expression. 
Figure 5: Kaplan Meier plots illustrating BCSS and IHC subgroups (negative, intermediate 
and highly positive group. 
Figure 6: Histogram representing a bimodal transcript level distribution for the ESR1 gene. 
Figure 7:  Kaplan Meier plots illustrating of breast cancer specific survival (BCSS) and 
transcriptomic subgroups (group one = negative, group two = intermediate, and group three 
= highly positive group)
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